phy Laser Mammography (CTLM(R)) system to be used as an
adjunct to mammography. The FDA has determined that the Company's clinical
study is a non-significant risk (NSR) investigational device study under
812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR
812). The CTLM system is limited by United States Federal Law to
investigational use only in the United States. The CTLM system has received
other registrations including CE, CMDCAS Canadian License, China SFDA, UL,
ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: http://www.imds.com
As contemplated by the provisions of the Safe Harbor section of the
Private Securities Litigation Reform Act of 1995, this news release may
contain forward-looking statements pertaining to future, anticipated, or
projected plans, performances and developments, as well as other statements
relating to future operations. All such forward-looking statements are
necessarily only estimates or predictions of future results or events and
there can be no assurance that actual results or events will not materially
differ from expectations. Further information on potential factors that
could affect Imaging Diagnostic Systems, Inc., is included in the Company's
filings with the Securities and Exchange Commission. We expressly disclaim
any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
(404) 261-1196
lcgroup@mindspring.com
Media Contact:
Elizabeth Williams
(954) 581-9800
williams@imds.com
'/>"/>SOURCE Imaging Diagnostic Systems, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Optimized Imaging of Protein Gels Stained with Coomassie
Brilliant Blue Dye2.
Detect Released Oligosaccharides Using the Eagle Eye II
Still Video Imaging System3.
Imaging Chemiluminescent Western Blots4.
Eagle Eye Optical Filter Optimized for Imaging Silver-Stained
Gels5.
Imaging and Analysis of DIGE Product Information Sheet, Rev B6.
The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System7.
Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System8.
The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System9.
The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System10.
The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System11.
Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells